Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Good clinical practice and phytotherapy

J Kusche1

  • 1Madaus AG, Köln, Germany.

Methods and Findings in Experimental and Clinical Pharmacology
|May 1, 1993
PubMed
Summary
This summary is machine-generated.

The European Community

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Bioavailability of 17 beta-estradiol after transdermal administration--dependence on the patch system].

Zentralblatt fur Gynakologie·1998
Same author

Retrospective study on laxative use and melanosis coli as risk factors for colorectal neoplasma.

Pharmacology·1993
Same author

Diamine oxidase activities in the large bowel mucosa of ulcerative colitis patients.

Agents and actions·1990
Same author

Early alterations of rat intestinal diamine oxidase activity by azoxymethane, an intestinal carcinogen.

Agents and actions·1989
Same author

The histamine-diamine oxidase system and mucosal proliferation under the influence of aminoguanidine and seventy percent resection of the rat small intestine.

Agents and actions·1989
Same author

Large bowel tumors and diamine oxidase (DAO) activity in patients: a new approach for risk group identification.

Agents and actions·1988
Same journal

[Proceedings of the XVIII TASPE Seminar, Granada, Spain, 4-5 February 2010].

Methods and findings in experimental and clinical pharmacology·2011
Same journal

[Treatment algorithm for gastrointestinal graft-versus-host disease].

Methods and findings in experimental and clinical pharmacology·2011
Same journal

[Treatment of chronic graft-versus-host disease with protein tyrosine kinase inhibitors].

Methods and findings in experimental and clinical pharmacology·2011
Same journal

[Classification of chronic graft-versus-host disease].

Methods and findings in experimental and clinical pharmacology·2011
Same journal

[Pegfilgrastim in hematopoietic stem cell transplantation].

Methods and findings in experimental and clinical pharmacology·2011
Same journal

[Allogeneic transplantation in multiple myeloma patients: results and recommendations in February 2010].

Methods and findings in experimental and clinical pharmacology·2011
See all related articles

Area of Science:

  • Pharmacology
  • Herbal Medicine Research
  • Clinical Trial Regulation

Background:

  • The European Community's Good Clinical Practice (GCP) Guideline, effective since June 1991, primarily targets innovative drugs.
  • This focus poses challenges for applying GCP standards to phytotherapy and herbal medicines.
  • Herbal medicines differ significantly from chemically defined drugs in composition and usage.

Purpose of the Study:

  • To evaluate the applicability and implications of the European GCP Guideline for herbal medicines.
  • To analyze the specific challenges and risks associated with implementing GCP standards for phytotherapy.
  • To consider the unique characteristics of herbal medicines in the context of clinical trial regulations.

Main Methods:

  • Comparative analysis of GCP standards versus the nature of herbal medicines.

Related Experiment Videos

  • Examination of differences between chemically defined drugs and herbal drug mixtures.
  • Assessment of preclinical data requirements versus long-term clinical experience with herbal remedies.

    • Main Results:

    • Herbal medicines, containing numerous substances, often have incomplete preclinical data but extensive clinical use.
    • Their distinct sensory properties make placebo creation difficult, impacting trial design.
    • GCP directive elements apply similarly to both chemically defined drugs and herbal medicines, despite inherent differences.

    Conclusions:

    • The unique nature of herbal medicines necessitates careful consideration when applying the European GCP Guideline.
    • Long-term clinical experience and tolerability of herbal medicines are key factors.
    • Adaptations or specific considerations within the GCP framework may be needed for herbal medicinal products.